Advanced search
Publication Cover
Future Medicinal Chemistry Volume 15, 2023 - Issue 16
Submit an article Journal homepage
43
Views
0
CrossRef citations to date
0
Altmetric
Review

Current Development of Pyrazole–Azole Hybrids With Anticancer Potential

Shu Zhang1 Hubei Key Laboratory of Pollution Damage Assessment & Environmental Health Risk Prevention & ControlHubei Provincial Academy of Eco-Environmental SciencesWuhanHubei430000PR ChinaORCID Iconhttps://orcid.org/0000-0003-2433-2563
ORCID Icon,
Yun Ye2 Technical Review Center for Administrative LicensingHubei Provincial Administration for Market RegulationWuhanHubei430000PR China
,
Qiang Zhang1 Hubei Key Laboratory of Pollution Damage Assessment & Environmental Health Risk Prevention & ControlHubei Provincial Academy of Eco-Environmental SciencesWuhanHubei430000PR China
,
Yang Luo1 Hubei Key Laboratory of Pollution Damage Assessment & Environmental Health Risk Prevention & ControlHubei Provincial Academy of Eco-Environmental SciencesWuhanHubei430000PR China
,
Zi-Chen Wang1 Hubei Key Laboratory of Pollution Damage Assessment & Environmental Health Risk Prevention & ControlHubei Provincial Academy of Eco-Environmental SciencesWuhanHubei430000PR China
,
Yi-Zhe Wu1 Hubei Key Laboratory of Pollution Damage Assessment & Environmental Health Risk Prevention & ControlHubei Provincial Academy of Eco-Environmental SciencesWuhanHubei430000PR China
,
Xiang-Pu Zhang1 Hubei Key Laboratory of Pollution Damage Assessment & Environmental Health Risk Prevention & ControlHubei Provincial Academy of Eco-Environmental SciencesWuhanHubei430000PR China
&
Chuan Yi1 Hubei Key Laboratory of Pollution Damage Assessment & Environmental Health Risk Prevention & ControlHubei Provincial Academy of Eco-Environmental SciencesWuhanHubei430000PR ChinaCorrespondence[email protected]
 show all
Pages 1527-1548 | Received 15 May 2023, Accepted 26 Jul 2023, Published online: 23 Aug 2023

References

  • Siegel RL , MillerKD , WagleNSet al. Cancer statistics, 2023. CA Cancer J. Clin.73(1), 17–48 (2023).
  • Hulvat MC . Cancer incidence and trends. Surg. Clin. N. Am.100(3), 469–481 (2020).
  • Ghebreyesus TA . The global agenda on cancer. IAEA Bull.63(1), 30–31 (2022).
  • International Agency for Research on Cancer . Cancertomorrow (2018). https://gco.iarc.fr/tomorrow/graphic-isotype?type=0&population=900&mode=population&sex=0&cancer=39&age_group=value&apc_male=0&apc_female=0
  • Zhang C , ZhaoJ , WangWHet al. Current advances in the application of nanomedicine in bladder cancer. Biomed. Pharmacother.157, e114062 (2023).
  • Alimardani V , RahiminezhadZ , DehghanKholdMet al. Nanotechnology-based cell-mediated delivery systems for cancer therapy and diagnosis. Drug Deliv. Transl. Res.13(1), 189–221 (2023).
  • Yalcin-Ozkat G . Molecular modeling strategies of cancer multidrug resistance. Drug Resist. Updates59, e100789 (2021).
  • Emran TB , ShahriarA , MahmudARet al. Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front. Oncol.12, e891652 (2022).
  • Prasher P , SharmaM. “Azole” as privileged heterocycle for targeting the inducible cyclooxygenase enzyme. Drug Dev. Res.82(2), 167–197 (2021).
  • Kamal R , KumarA , KumarR. Synthetic strategies for 1,4,5/4,5-substituted azoles: a perspective review. J. Heterocyclic Chem.60(1), 5–17 (2023).
  • Prasher P , SharmaM , ZacconiFet al. Synthesis and anticancer properties of ‘azole’ based chemotherapeutics as emerging chemical moieties: a comprehensive review. Curr. Org. Chem.25(6), 654–668 (2021).
  • Bhaumik PK , GhoshK , ChattopadhyayS. Synthetic strategies, crystal structures and biological activities of metal complexes with the members of azole family: a review. Polyhedron200, e115093 (2021).
  • Shaikh J , PatelK , KhanT. Advances in pyrazole-based scaffold as cyclin-dependent kinase 2 inhibitors for the treatment of cancer. Mini-Rev. Med. Chem.22(8), 1197–1215 (2022).
  • Bennani FE , DoudachL , CherrahYet al. Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line. Bioorg. Chem.97, e103470 (2020).
  • Satbir M , MohiniK , RavinderPet al. Recent progress in anticancer agents incorporating pyrazole scaffold. Mini-Rev. Med. Chem.22(1), 115–163 (2022).
  • Alam MJ , AlamO , NaimMet al. Recent advancement in drug design and discovery of pyrazole biomolecules as cancer and inflammation therapeutics. Molecules27(24), e8708 (2022).
  • Ardevines S , Marqués-LópezE , HerreraRP. Heterocycles in breast cancer treatment: the use of pyrazole derivatives. Curr. Med. Chem.30(10), 1145–1174 (2023).
  • Altintop MD , ÖzdemirA , IlginSet al. Synthesis and biological evaluation of new pyrazole-based thiazolyl hydrazone derivatives as potential anticancer agents. Lett. Drug Des. Dis.11(7), 833–839 (2014).
  • Szumilak M , Wiktorowska-OwczarekA , StanczakA. Hybrid drugs – a strategy for overcoming anticancer drug resistance?Molecules26(9), e2601 (2021).
  • Soltan OM , ShomanME , Abdel-AzizSAet al. Molecular hybrids: a five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. Eur. J. Med. Chem.225, e113768 (2021).
  • Yamani A , Zdżalik-BieleckaD , LipnerJet al. Discovery and optimization of novel pyrazole–benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1–3). Eur. J. Med. Chem.210, e112990 (2021).
  • Zarczynska I , Gorska-ArciszM , CortezAJet al. P38 mediates resistance to fgfr inhibition in non-small cell lung cancer. Cells10(12), e3363 (2021).
  • Kitowska K , Gorska-ArciszM , AntounDet al. MET-Pyk2 axis mediates acquired resistance to FGFR inhibition in cancer cells. Front. Oncol.11, e633410 (2021).
  • Wang Z , CaiJ , RenJet al. Discovery of a potent FLT3 inhibitor (LT-850-166) with the capacity of overcoming a variety of FLT3 mutations. J. Med. Chem.64(19), 14664–14701 (2021).
  • Xi Q , WangM , JiaWet al. Design, synthesis, and biological evaluation of amidobenzimidazole derivatives as stimulator of interferon genes (STING) receptor agonists. J. Med. Chem.63(1), 260–282 (2020).
  • Gao JM , JiK , LiuRCet al. Design, synthesis and in vitro antitumor evaluation of novel pyrazole–benzimidazole derivatives. Bioorg. Med. Chem. Lett.43, e128097 (2021).
  • Sagam RR , NukalaSK , NagavathRet al. Synthesis of new morpholine-benzimidazole-pyrazole hybrids as tubulin polymerization inhibiting anticancer agents. J. Mol. Struct.1268, e133692 (2022).
  • Kong B , ZhuZ , LiHet al. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy. Eur. J. Med. Chem.227, e113953 (2022).
  • Galal SA , KhairatSHM , AliHIet al. Part II: New candidates of pyrazole–benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors. Eur. J. Med. Chem.144, 859–873 (2018).
  • Galal SA , OmarMA , KhairatSHMet al. Design and synthesis of new pyrazolylbenzimidazoles as sphingosine kinase-1 inhibitors. Med. Chem. Res.30(9), 1614–1634 (2021).
  • Carter DM , SpeckerE , MałeckiPHet al. Enhanced properties of a benzimidazole benzylpyrazole lysine demethylase inhibitor: mechanism-of-action, binding site analysis, and activity in cellular models of prostate cancer. J. Med. Chem.64(19), 14266–14282 (2021).
  • Obaid RJ . New benzimidazole derivatives: design, synthesis, docking, and biological evaluation. Arab. J. Chem.16(2), e104505 (2023).
  • Wang YT , ShiTQ , ZhuHLet al. Synthesis, biological evaluation and molecular docking of benzimidazole grafted benzsulfamide-containing pyrazole ring derivatives as novel tubulin polymerization inhibitors. Bioorg. Med. Chem.27(3), 502–515 (2019).
  • Sivaramakarthikeyan R , IniyavalS , SaravananVet al. Molecular hybrids integrated with benzimidazole and pyrazole structural motifs: design, synthesis, biological evaluation, and molecular docking studies. ASC Omega5, 10089–10098 (2020).
  • Khairat SHM , OmarMA , RagabFAFet al. Design, synthesis, and biological evaluation of novel benzimidazole derivatives as sphingosine kinase 1 inhibitor. Arch. Pharm.354(9), e2100080 (2021).
  • Sivaramakarthikeyan R , IniyavalS , LimWMet al. Pyrazolylphenanthroimidazole heterocycles: synthesis, biological and molecular docking studies. New J. Chem.44(45), 19612–19622 (2020).
  • Rani CS , ReddyAG , SusithraEet al. Synthesis and anticancer evaluation of amide derivatives of imidazo-pyridines. Med. Chem. Res.30(1), 74–83 (2021).
  • Kang SJ , LeeJW , ChungSHet al. Synthesis and anti-tumor activity of imidazopyrazines as TAK1 inhibitors. Eur. J. Med. Chem.163, 660–670 (2019).
  • Yu J , ZhouP , HuMet al. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants. Eur. J. Med. Chem.182, e111608 (2019).
  • Zheng YG , WangJA , MengLet al. Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors. Eur. J. Med. Chem.209, e112934 (2021).
  • Inceler N , OzkanY , TuranNet al. Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents. MedChemComm9(5), 795–811 (2018).
  • Kuthyala S , SheikhS , PrabhuAet al. Synthesis, characterization, and anticancer studies of some pyrazole-based hybrid heteroatomics. ChemistrySelect5(35), 10827–10834 (2020).
  • Abdellatif KRA , FadalyWAA , MostafaYAet al. Thiohydantoin derivatives incorporating a pyrazole core: design, synthesis and biological evaluation as dual inhibitors of topoisomerase-I and cycloxygenase-2 with anti-cancer and anti-inflammatory activities. Bioorg. Chem.91, e103132 (2019).
  • Demjén A , AlföldiR , AngyalAet al. Synthesis, cytotoxic characterization, and SAR study of imidazo[1,2-b]pyrazole-7-carboxamides. Arch. Pharm.351(7), e1800062 (2018).
  • Szebeni GJ , BalogJA , DemjénAet al. Imidazo[1,2-b]pyrazole-7-carboxamides induce apoptosis in human leukemia cells at nanomolar concentrations. Molecules23(11), e2845 (2018).
  • Brullo C , RapettiF , AlfeiSet al. Discovery of new antiproliferative imidazopyrazole acylhydrazones able to interact with microtubule systems. ChemMedChem15, 961–969 (2020).
  • Zheng YG , PeiX , XiaDXet al. Design, synthesis, and cytotoxic activity of novel 2H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidine derivatives. Bioorg. Chem.109, e104711 (2021).
  • Yang SM , YoshiokaM , StrovelJWet al. Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases. Bioorg. Med. Chem. Lett.29(10), 1220–1226 (2019).
  • Ahmad I , AouadiK , Gad-ElkareemMAMet al. Design, synthesis, in vitro anticancer and antimicrobial evaluation, SAR analysis, molecular docking and dynamic simulation of new pyrazoles, triazoles and pyridazines based isoxazole. J. Mol. Struct.1264, e133312 (2022).
  • Chandavaram PS , MaddiralaSJ , VidavalurSet al. Design, synthesis and biological evaluation of isoxazole bearing N-Arylpyrazole derivatives as anticancer agents. Chem. Data Collect.41, e100938 (2022).
  • Zhao Y , ZhouB , BaiLet al. Structure-based discovery of CF53 as a potent and orally bioavailable bromodomain and extra-terminal (BET) bromodomain inhibitor. J. Med. Chem.61(14), 6110–6120 (2018).
  • Bobbala RR , KolliB , RavulaS. Synthesis of novel isoxazole functionalized pyrazolo[3,4-b]pyridine derivatives; their anticancer activity. J. Heterocyclic Chem.57, 2535–2538 (2020).
  • Bhatt TD , GojiyaDG , KalavadiyaPLet al. Rapid, greener and ultrasound irradiated one-pot synthesis of 4-(substituted-1H-pyrazol-4-yl)methylene)-3- isopropylisoxazol-5(4H)-ones and their in vitro anticancer activity. ChemistrySelect4, 11125–11129 (2019).
  • Aljohani GF , El-HagFAA , BekheitMSet al. An efficient one-pot synthesis of certain stereoselective spiro[pyrazole-4,5′-isoxazoline]-5-one derivatives: In vitro evaluation of antitumor activities, molecular docking and in silico ADME predictions. Chem. Res. Chin. Univ.38(4), 1073–1082 (2022).
  • Khan I , GanapathiT , RehmanMDMet al. New indenopyrazole linked oxadiazole conjugates as anti-pancreatic cancer agents: design, synthesis, in silico studies including 3D-QSAR analysis. Bioorg. Med. Chem. Lett.44, e128094 (2021).
  • Ravinaik B , RamachandranD , RaoMVB. Design, synthesis and anticancer evaluation of 1,2,4-oxadiazole bearing isoxazole-pyrazole derivatives. Lett. Org. Chem.17(5), 352–359 (2020).
  • Kaur J , BhardwajA , WuestF. Development of fluorescence imaging probes for labeling COX-1 in live ovarian cancer cells. ACS Med. Chem. Lett.12(5), 798–804 (2021).
  • Dai H , GeS , GuoJet al. Development of novel bis-pyrazole derivatives as antitumor agents with potent apoptosis induction effects and DNA damage. Eur. J. Med. Chem.143, 1066–1076 (2018).
  • Farooq M , SharmaA , AlmarhoonZet al. Design and synthesis of mono-and di-pyrazolyl-s-triazine derivatives, their anticancer profile in human cancer cell lines, and in vivo toxicity in zebrafish embryos. Bioorg. Chem.87, 457–464 (2019).
  • Gupta A , IqbalS , RoohiAet al. Visible light-promoted green and sustainable approach for one-pot synthesis of 4,4′-(arylmethylene)bis(1H-pyrazol-5-ols), in vitro anticancer activity, and molecular docking with Covid-19 Mpro. ACS Omega7(38), 34583–34598 (2022).
  • Bakhotmah DA , AliTE , AssiriMAet al. Synthesis of some novel 2-{pyrano[2,3-c]pyrazoles-4-ylidene}malononitrile fused with pyrazole, pyridine, pyrimidine, diazepine, chromone, pyrano[2,3-c]pyrazole and pyrano[2,3-d]pyrimidine systems as anticancer agents. Polycylic Aromatic Compd42(5), 2136–2150 (2022).
  • Chinthaparthi RR , ChittiboenaVL , JorepalliSet al. Green synthesis and anticancer activity of tetrahydrodipyrazolo[3,4-b:4′,3′-e]pyridines catalyzed by phospho sulfonic acid. J. Heterocyclic Chem.58(5), 1104–1116 (2021).
  • Farag PS , AboulMagdAM , HemdanMMet al. Annulated pyrazole derivatives as a novel class of urokinase (uPA) inhibitors: green synthesis, anticancer activity, DNA-damage evaluation, and molecular modelling study. Bioorg. Chem.130, e106231 (2023).
  • Ostache NC , ParisA , HiebelMAet al. Cytotoxic evaluation of original pyrazolo[3,4-d]thiazoles and pyrazolo[3,4-c]pyrazoles. Farmacia70(2), 258–265 (2022).
  • Wang XR , WangS , LiWBet al. Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors. Eur. J. Med. Chem.213, e113192 (2021).
  • Halim PA , SharkawiSMZ , LabibMB. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition. Bioorg. Chem.131, e106273 (2023).
  • Ali MM , DawoodDH , MahmoudAEet al. Synthesis and molecular docking study of new pyrazole derivatives as potent anti-breast cancer agents targeting VEGFR-2 kinase. Bioorg. Chem.101, e103916 (2020).
  • Nawaz F , AlamO , PerwezAet al. Design, synthesis, molecular docking, and anticancer evaluation of pyrazole linked pyrazoline derivatives with carbothioamide tail as EGFR kinase inhibitors. Anti-Cancer Agents Med. Chem.21(1), 42–60 (2021).
  • Akhtar W , MarellaA , AlamMMet al. Design and synthesis of pyrazole-pyrazoline hybrids as cancer-associated selective COX-2 inhibitors. Arch. Pharm.354(1), e2000116 (2021).
  • Gong Y , WuFX , WangMSet al. Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance. Eur. J. Med. Chem.241, e114654 (2022).
  • Zhuo LS , WangMS , WuFXet al. Discovery of next-generation tropomyosin receptor kinase inhibitors for combating multiple resistance associated with protein mutation. J. Med. Chem.64(20), 15503–15514 (2021).
  • Yin Y , ChenCJ , YuRNet al. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold. Bioorg. Med. Chem.27(8), 1562–1576 (2019).
  • Husseiny EM . Synthesis, cytotoxicity of some pyrazoles and pyrazolo[1,5-a]pyrimidines bearing benzothiazole moiety and investigation of their mechanism of action. Bioorg. Chem.102, e104053 (2020).
  • Abdellatif KRA , AminNH , BelalAet al. Design, synthesis, molecular docking and antiproliferative activity of some novel benzothiazole derivatives targeting EGFR/HER2 and TS. Bioorg. Chem.101, e103976 (2020).
  • Reddy VG , ReddyTS , JadalaCet al. Pyrazolo-benzothiazole hybrids: synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model. Eur. J. Med. Chem.182, e111609 (2019).
  • Nagaraju B , KovvuriJ , KumarCGet al. Synthesis and biological evaluation of pyrazole linked benzothiazole-β-naphthol derivatives as topoisomerase I inhibitors with DNA binding ability. Bioorg. Med. Chem.27(5), 708–720 (2019).
  • Deshineni R , AryaCG , BanothuJet al. Synthesis, anticancer and antibacterial evaluation of novel 1,3-disubstituted-1H-pyrazole-4-yl-methylene embedded fused thiazolo[2,3-b]quinazolinones. Chem. Data Collect.30, e100546 (2020).
  • Mamatha SV , BelagaliSL , BhatMet al. Design, synthesis and characterization of novel benzothiazolyl pyrazoles as potential antitubercular scaffold. Chem. Data Collect.41, e100930 (2022).
  • Liu DC , GaoMJ , HuoQet al. Design, synthesis, and apoptosis-promoting effect evaluation of novel pyrazole with benzo[d]thiazole derivatives containing aminoguanidine units. J. Enzym. Inhib. Med. Chem.34(1), 829–837 (2019).
  • Hassan AY , SargMT , HusseinEM. Design, synthesis, and anticancer activity of novel benzothiazole analogues. J. Heterocyclic Chem.56(4), 1437–1457 (2019).
  • Palabindela R , GudaR , RameshGet al. Curcumin based pyrazole-thiazole hybrids as antiproliferative agents: Synthesis, pharmacokinetic, photophysical properties, and docking studies. J. Mol. Struct.1275, e134633 (2023).
  • El-Fakharany EM , DawoudNTA , El-GendiHet al. Consolidated antimicrobial and anticancer activities through newly synthesized novel series of pyrazoles bearing indazolylthiazole moiety: characterization and molecular docking. Egypt. J. Chem.64(11), 6565–6576 (2021).
  • Chen Y , GaoD , KongFet al. Discovery of new fluorescent thiazole-pyrazoline derivatives as autophagy inducers by inhibiting mTOR activity in A549 human lung cancer cells. Cell Death Dis.11(7), e551 (2020).
  • Mamidala S , AravilliRK , RameshGet al. A facile one-pot, three-component synthesis of a new series of thiazolyl pyrazole carbaldehydes: In vitro anticancer evaluation, in silico ADME/T, and molecular docking studies. J. Mol. Struct.1236, e130356 (2021).
  • Bandaru CM , PoojithN , JadavSSet al. Design, synthesis, anticancer evaluation, and molecular docking studies of thiazole-pyrimidine linked amide derivatives. Polycyclic Aromatic Compd42(8), 5368–5384 (2022).
  • El Azab IH , SaiedEM , OsmanAAet al. Novel N-bridged pyrazole-1-carbothioamides with potential antiproliferative activity: design, synthesis, in vitro and in silico studies. Future Med. Chem.13(20), 1743–1766 (2021).
  • Bhat M , PoojaryB , KalalBSet al. Synthesis and evaluation of thiazolidinone-pyrazole conjugates as anticancer and antimicrobial agents. Future Med. Chem.10(9), 1017–1036 (2018).
  • Kolluri PK , GurrapuN , SubhashiniAet al. Design, synthesis of novel (Z)-2-(3-(4-((3-benzyl-2,4-dioxothiazolidin-5-ylidene)methyl)-1-phenyl-1H-pyrazol-3-yl)phenoxy)-N-arylacetamide derivatives: evaluation of cytotoxic activity and molecular docking studies. J. Mol. Struct.1202, e127300 (2020).
  • Abbas HAS , AbdEl-Karim SS. Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono-thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents. Bioorg. Chem.89, e103035 (2019).
  • Abd El-Salam HA , FathyU , ZayedEMet al. Design, synthesis, cytotoxic activity and molecular docking studies of naphthyl pyrazolyl thiazole derivatives as anticancer agents. ChemistrySelect8(2), E202203956 (2023).
  • Abd El Wahab SM , AlaaeddineR , AllamRMet al. Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting cyclooxygenase-2,15-lipoxygenase and tumor-associated carbonic anhydrases. Eur. J. Med. Chem.200, e112439 (2020).
  • Lakkakula R , RoyA , MukkantiKet al. Synthesis and anticancer activity of 1,2,3-triazole fused N-arylpyrazole derivatives. Russ. J. Gen. Chem.89(4), 831–835 (2019).
  • Khan MF , AnswerT , BakhtAet al. Unveiling novel diphenyl-1H-pyrazole based acrylates tethered to 1,2,3-triazole as promising apoptosis inducing cytotoxic and anti-inflammatory agents. Bioorg. Chem.87, 667–678 (2019).
  • Jonnalagadda SB , KerruN , MaddilaSet al. Design, synthesis, anticancer activity and molecular docking analysis of novel dinitrophenylpyrazole bearing 1,2,3-triazoles. J. Mol. Struct.1243, e130865 (2021).
  • Oubella A , BimoussaA , ByadiSet al. Design, synthesis, in vitro anticancer activity, and molecular docking studies of new (R)-carvone-pyrazole-1,2,3-triazoles. J. Mol. Struct.1265, e133383 (2022).
  • Subhashini NJP , KumarKP , KumarEPet al. Design and synthesis of novel (Z)-5-((1,3-diphenyl-1H-pyrazol-4-yl) methylene)-3-((1-substituted phenyl-1H-1,2,3-triazol-4-yl)methyl) thiazolidine-2,4-diones: a potential cytotoxic scafolds and their molecular modeling studies. Mol. Diversity25, 2017–2033 (2021).
  • Kolluri PK , GurrapuN , EdigiPKet al. Design, synthesis of (Z)-3-benzyl-5-((1-phenyl-3-(3-((1-substituted phenyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1H-pyrazol-4-yl)methylene)thiazolidine-2,4-dione analogues as potential cytotoxic agents. J. Heterocyclic Chem.56(12), 3244–3256 (2019).
  • Ashok D , DharavathR , GunduSet al. Microwave-assisted synthesis and in vitro antiproliferative activity of some novel 1,2,3-triazole-based pyrazole aldehydes and their benzimidazole derivatives. Med. Chem. Res.29, 699–706 (2020).
  • Mohan G , SridharG , LaxminarayanaEet al. Synthesis and biological evaluation of 1,2,4-oxadiazole incorporated 1,2,3-triazole-pyrazole derivatives as anticancer agents. Chem. Data Collect.34, e100735 (2021).
  • Seliem IA , PandaSS , GirgisASet al. Development of isatin-based Schiff bases targeting VEGFR-2 inhibition: synthesis, characterization, antiproliferative properties, and QSAR studies. ChemMedChem17(13), E202200164 (2022).
  • Chekir S , DebbabiM , RegazzettiAet al. Design, synthesis and biological evaluation of novel 1,2,3-triazole linked coumarinopyrazole conjugates as potent anticholinesterase, anti-5-lipoxygenase, anti-tyrosinase and anti-cancer agents. Bioorg. Chem.80, 189–194 (2018).
  • Abdellatif KRA , ElshaierYAMM , FadalyWAAet al. New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies. Bioorg. Chem.98, e103752 (2020).
  • Zhang L , ZhaoJ , ZhangBet al. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: synthesis, SAR study, and biological activity. Eur. J. Med. Chem.150, 809–816 (2018).
  • Nossier ES , AbdEl-Karim SS , KhalifaNMet al. Kinase inhibitory activities and molecular docking of a novel series of anticancer pyrazole derivatives. Molecules23(12), e3074 (2018).
  • Mallisetty NM , GanipisettiH , MajhiDet al. Synthesis and biological activity evaluation of pyrazole-1,2,4-triazole hybrids: a computer-aided docking studies. Curr. Drug Discov. Technol.20(2), E251122211263 (2023).
  • Mandour AA , NassarIF , AalMTAet al. Synthesis, biological evaluation, and in silico studies of new CDK2 inhibitors based on pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold with apoptotic activity. J. Enzym. Inhib. Med. Chem.37(1), 1957–1973 (2022).
  • Bagal SK , GregsonC , O'DonovanDHet al. Diverse, potent, and efficacious inhibitors that target the EED subunit of the polycomb repressive complex 2 methyltransferase. J. Med. Chem.64(23), 17146–17183 (2021).
  • Halim KNM , RizkSA , El-HashashMAet al. Straightforward synthesis, antiproliferative screening, and density functional theory study of some pyrazolylpyrimidine derivatives. J. Heterocyclic Chem.58(2), 636–645 (2021).
  • Pogaku V , KrishnanR , BasavojuS. Synthesis and biological evaluation of new benzo[d][1,2,3]triazol-1-yl-pyrazole-based dihydro-[1,2,4]triazolo[4,3-a]pyrimidines as potent antidiabetic, anticancer and antioxidant agents. Res. Chem. Intermed.47(2), 551–571 (2021).
  • Huo JL , WangS , YuanXHet al. Discovery of [1,2,4]triazolo[1,5-a]pyrimidines derivatives as potential anticancer agents. Eur. J. Med. Chem.211, e113108 (2021).
  • Chen D , LuT , YanZet al. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins. Eur. J. Med. Chem.182, e111633 (2019).
  • Qin C , HuY , ZhouBet al. Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression. J. Med. Chem.61(15), 6685–6704 (2018).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.